Press Room

4 December 2023

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium^® Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

31 October 2023

7 December 2022

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS^® 2022

28 April 2022

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

2 December, 2021

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

20 May, 2021

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score^® Test in Node-Positive Early-Stage Breast Cancer

25 March, 2021

New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score^® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

9 December, 2020

RxPONDER study results demonstrate that the Oncotype DX^® Test can now spare chemotherapy use in the majority of women with node-positive early-stage breast cancer

2 October, 2020

New real-world evidence further demonstrates the Oncotype DX Breast Recurrence Score^® Test’s clinical utility, beyond clinical risk factors, in guiding chemotherapy treatment decisions in patients with early-stage breast cancer

29 May, 2020

New data and society guidelines support value of Oncotype DX Breast Recurrence Score^® Test in guiding neoadjuvant treatment decisions for newly diagnosed patients

14 May, 2020

New Oncotype DX^® real-world evidence shows for the first time the practice-changing impact of TAILORx results

12 December, 2019

New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

2 October, 2019

New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment

21 June, 2019

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test

4 June, 2019

Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

25 March, 2019

Evidence from UK hospitals supports the value of the Oncotype DX test in avoiding unnecessary chemotherapy for patients with node-positive breast cancer

19 December, 2018

NICE expands recommendation for the Oncotype DX test to more patients with early-stage breast cancer

11 December, 2018

New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions

22 October, 2018

New real-world evidence confirms value of the Oncotype DX test in clinical practice for patients with early-stage breast cancer

3 June, 2018

Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving

11 December, 2017

New results from large registry with 10-year follow up show excellent outcomes for patients with low Oncotype DX Breast Recurrence Score^® results treated with hormonal therapy alone

11 September, 2017

Genomic test shows that half of under-40s with early breast cancer have excellent prognosis despite not having chemotherapy treatment

12 July, 2017

Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer

13 June, 2017

New data show important role of genomic testing in treatment of older breast cancer patients

20 March, 2017

Genomic Health’s Oncotype DX breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal

6 February, 2017

NHS adoption of Oncotype DX test leads to substantial reduction in unnecessary chemotherapy for UK breast cancer patients

12 December, 2016

New data demonstrate that Oncotype DX can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy

10 October, 2016

Large study shows older breast cancer patients have worse outcomes

20 June, 2016

Updated NICE quality standard recommends Oncotype DX^® in early-stage breast cancer

6 June, 2016

Oncotype DX presentations at 2016 ASCO^® annual meeting reinforce Genomic Health’s leadership in optimising breast cancer treatment

31 May, 2016

Innovative Oncotype DX test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients

11 March, 2016

Five-year outcomes results from European ‘PlanB’ study show that breast cancer patients with low Oncotype DX Recurrence Score^® results can be spared chemotherapy despite having high-risk disease by traditional measures